These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35321625)

  • 1. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
    Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
    Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
    Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
    J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
    Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
    J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case-control study.
    Bhattacharya D; Kanungo S; Palo SK; Kshatri JS; Pattnaik M; Ghosal S; Mohapatra P; Rao CM; Sahoo A; Mishra RP; Mishra S; Mohanta AR; Doley C; Pati S
    Front Public Health; 2022; 10():1041586. PubMed ID: 36684990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior vaccination with Covishield
    Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
    Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
    Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R
    BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covid-19 Vaccines Available in India.
    Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
    Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
    Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S
    JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy).
    Basso P; Negro C; Cegolon L; Larese Filon F
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215930
    [No Abstract]   [Full Text] [Related]  

  • 19. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
    Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
    J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.